Table 1.
Patient characteristics.
| All patients (n = 167) |
Typical NS (n = 124) |
SV (n = 43) |
|
|---|---|---|---|
| Age, years | 31 | 30 | 31 |
| Median, range | 17–75 | 17–75 | 20–53 |
| Male | 85 (50%) | 60 (58%) | 25 (48%) |
| ECOG 0–1 | 161 (96%) | 119 (97%) | 42 (96%) |
| Stage (III/IV) | 65 (39%) | 48 (38%) | 17 (41%) |
| >3 node site | 44 (26%) | 34 (27%) | 10 (23%) |
| ⩽3 | 78 (47%) | 59 (48%) | 19 (44%) |
| N/A | 45 (27%) | 31 (25%) | 14 (33%) |
| B symptoms | 82 (49%) | 57 (46%) | 26 (60%)† |
| Bulky | 41 (25%) | 31 (25%) | 10 (23%) |
| Nonbulky | 91 (55%) | 70 (56%) | 21 (49%) |
| N/A | 35 (20%) | 23 (19%) | 12 (28%) |
| Treatment | |||
| ABVD | 152 (91%) | 113 (91%) | 39 (91%) |
| Stanford V | 4 (2.5%) | 3 (2.5%) | 1 (2%) |
| COPP/ABV | 6 (3.5%) | 3 (2.5%) | 3 (7%) |
| Other* | 5 (3%) | 5 (4%) | — |
| XRT | 62 (38%) | 45 (36.8%) | 17 (43%) |
| HDT/ASCT | 44 (27%) | 28 (23%) | 16 (37%)‡ |
| No ASCT | 114 (68%) | 93 (75%) | 21 (49%) |
| N/A | 9 (5%) | 3 (2%) | 6 (14%) |
*
Other, ABV, AVD, COPP and MOPP/ABV.
†
p = 0.07; ‡p = 0.016.
ABV, doxorubicin, bleomycin and vinblastine; ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; ASCT, autologous stem cell transplant; AVD, doxorubicin, vinblastine and dacarbazine; COPP, cyclophosphamide, vincristine, procarbazine and prednisone; HDT, high dose therapy; MOPP, mechlorethamine, vincristine, procarbazine and prednisone; N/A, not available; NS, nodular sclerosis; Stanford V, doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone; SV, syncytial variant; XRT, radiation.